Company profile: Newron Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for central and peripheral nervous system diseases, including Xadago (safinamide), an approved treatment for Parkinson’s disease available in the EU, Switzerland, the U.S., Canada, Australia, New Zealand, and Israel; and investigational candidates Evenamide as a potential first add-on therapy for positive symptoms of schizophrenia, and Ralfinamide for specific rare pain indications.
Products and services
- Evenamide: An investigational-stage add-on therapy in development targeting positive symptoms of schizophrenia, positioned as a potential first add-on therapy for patients with these symptoms
- Ralfinamide: A development-stage drug being advanced for patients with specific rare pain indications, addressing rare pain conditions identified as distinct indications
- Xadago (safinamide): A market-authorized medication for Parkinson’s disease, commercialized and available in the European Union, Switzerland, USA, Canada, Australia, New Zealand, and Israel
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Newron Pharmaceuticals
Allay Therapeutics
HQ: United States
Website
- Description: Provider of analgesic products for post-surgical pain management and recuperation, including ATX-101, which delivers controlled-release bupivacaine at the surgical site to provide weeks of pain relief after total knee replacement. Offers a proprietary technology platform combining non-opioid analgesics and biopolymers to create dissolvable candidates for localized, extended pain relief.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allay Therapeutics company profile →
Cosman Medical
HQ: United States
Website
- Description: Provider of radiofrequency (RF) generators, electrodes, and cannulae for neurosurgery and pain management in interventional anesthesiology and podiatry, leveraging RF nerve ablation with a 60-year track record in medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cosman Medical company profile →
MAP Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel inhalation therapies under development for respiratory and systemic diseases, with proprietary product candidates including Unit Dose Budesonide for pediatric asthma (children six months to eight years) and MAP0004 for migraine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MAP Pharmaceuticals company profile →
Reverse Medical
HQ: United States
Website
- Description: Provider of commercial-stage medical devices focused on revascularizing patients experiencing acute ischemic stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reverse Medical company profile →
Transition Therapeutics
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapeutics targeting disease indications with large markets. Lead products include ELND005 for the treatment of Alzheimer’s disease and TT223 for the treatment of diabetes, with an emerging pipeline of preclinical drug candidates acquired externally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transition Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Newron Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Newron Pharmaceuticals
2.2 - Growth funds investing in similar companies to Newron Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Newron Pharmaceuticals
4.2 - Public trading comparable groups for Newron Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →